Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$7.95	$8.72	$7.35 ▼ $13.70	$2.43B	0.1	476,833 shs	259,464 shs
CRNX Crinetics Pharmaceuticals	$34.65 +4.1%	$30.17	$24.10 ▼ $62.53	$3.14B	0.28	980,865 shs	1.77 million shs
HCM HUTCHMED	$15.27 -0.3%	$16.37	$11.51 ▼ $21.50	$2.62B	0.45	53,651 shs	49,871 shs
NUVB Nuvation Bio	$3.16 +7.0%	$2.45	$1.54 ▼ $3.45	$1.02B	1.36	4.57 million shs	6.46 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	0.00%	-1.00%	-10.37%	-24.29%	-29.96%
CRNX Crinetics Pharmaceuticals	+4.05%	+13.98%	+22.79%	+7.21%	-33.39%
HCM HUTCHMED	-0.33%	+2.07%	-11.63%	+0.07%	-12.44%
NUVB Nuvation Bio	+7.16%	+7.16%	+36.62%	+27.00%	+5.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVO Alvotech	3.0009 of 5 stars	3.3	2.0	0.0	2.1	0.0	1.9
CRNX Crinetics Pharmaceuticals	3.7996 of 5 stars	3.4	0.0	3.7	4.2	2.5	0.0
HCM HUTCHMED	2.0179 of 5 stars	3.5	2.0	0.0	0.0	0.0	1.9
NUVB Nuvation Bio	2.4884 of 5 stars	3.6	1.0	0.0	2.7	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	2.50	Moderate Buy	$14.00	76.10% Upside
CRNX Crinetics Pharmaceuticals	2.78	Moderate Buy	$68.86	98.72% Upside
HCM HUTCHMED	3.00	Buy	$28.00	83.37% Upside
NUVB Nuvation Bio	3.17	Buy	$7.33	132.36% Upside

Current Analyst Ratings Breakdown

Latest NUVB, CRNX, ALVO, and HCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ALVO Alvotech	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2025	CRNX Crinetics Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$90.00 ➝ $86.00
8/11/2025	HCM HUTCHMED	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/8/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
7/22/2025	HCM HUTCHMED	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $28.00
7/18/2025	ALVO Alvotech	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $14.00
7/10/2025	CRNX Crinetics Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$36.00
6/27/2025	CRNX Crinetics Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/17/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$10.00 ➝ $6.00
6/11/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00

(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$491.98M	4.87	N/A	N/A	($0.57) per share	-13.95
CRNX Crinetics Pharmaceuticals	$1.39M	2,344.25	N/A	N/A	$12.44 per share	2.79
HCM HUTCHMED	$630.20M	4.23	$0.29 per share	52.26	$7.12 per share	2.14
NUVB Nuvation Bio	$7.87M	137.26	N/A	N/A	$1.09 per share	2.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	-$231.86M	$0.23	34.57	39.75	N/A	11.26%	-38.36%	9.28%	11/12/2025 (Estimated)
CRNX Crinetics Pharmaceuticals	-$298.41M	-$4.11	N/A	N/A	N/A	N/A	-32.28%	-29.45%	11/11/2025 (Estimated)
HCM HUTCHMED	$37.73M	N/A	0.00	10.46	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	-$567.94M	-$0.63	N/A	N/A	N/A	-1,413.43%	-46.14%	-36.04%	11/5/2025 (Estimated)

Latest NUVB, CRNX, ALVO, and HCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALVO Alvotech	-$0.26	$0.14	+$0.40	$0.14	$120.51 million	$116.02 million
8/7/2025	Q2 2025	CRNX Crinetics Pharmaceuticals	-$1.13	-$1.23	-$0.10	-$1.23	$0.52 million	$1.03 million
8/7/2025	Q2 2025	NUVB Nuvation Bio	-$0.17	-$0.17	N/A	-$0.17	$0.42 million	$4.83 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.82	1.27
CRNX Crinetics Pharmaceuticals	N/A	17.80	17.80
HCM HUTCHMED	0.05	4.65	4.51
NUVB Nuvation Bio	0.13	9.39	9.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
CRNX Crinetics Pharmaceuticals	98.51%
HCM HUTCHMED	8.82%
NUVB Nuvation Bio	61.67%

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	N/A
CRNX Crinetics Pharmaceuticals	4.60%
HCM HUTCHMED	3.60%
NUVB Nuvation Bio	29.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,032	301.48 million	N/A	Not Optionable
CRNX Crinetics Pharmaceuticals	210	94.18 million	88.53 million	Optionable
HCM HUTCHMED	1,811	174.42 million	168.14 million	Not Optionable
NUVB Nuvation Bio	60	342.27 million	239.83 million	Optionable

NUVB, CRNX, ALVO, and HCM Headlines

Recent News About These Companies

Nuveen LLC Takes $799,000 Position in Nuvation Bio Inc. $NUVB

2 hours ago | marketbeat.com

Is Technical Momentum and Analyst Optimism Reshaping the Investment Case for Nuvation Bio (NUVB)?

September 1 at 8:05 PM | finance.yahoo.com

Nuvation Bio Inc. (NYSE:NUVB) Receives $7.33 Average PT from Brokerages

August 31, 2025 | americanbankingnews.com

Vanguard Group Inc. Cuts Position in Nuvation Bio Inc. $NUVB

August 30, 2025 | marketbeat.com

Why I'm Avoiding Nuvation Bio Despite Its Recent FDA Approval

August 29, 2025 | seekingalpha.com

Nuvation Bio: What To Expect From IBTROZI Launch?

August 28, 2025 | seekingalpha.com

Nuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of "Buy" from Analysts

August 28, 2025 | marketbeat.com

Nuvation Bio to Participate in Upcoming Investor Conferences

August 27, 2025 | businesswire.com

Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy?

August 27, 2025 | zacks.com

H.C. Wainwright Reiterates a Buy Rating on Nuvation Bio (NUVB)

August 26, 2025 | msn.com

Nuvation Bio Inc. $NUVB Shares Acquired by Algert Global LLC

August 24, 2025 | marketbeat.com

Wall Street Zen Upgrades Nuvation Bio (NYSE:NUVB) to Hold

August 18, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Trading 9.7% Higher - Still a Buy?

August 15, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Announces Quarterly Earnings Results

August 11, 2025 | marketbeat.com

Royal Bank Of Canada Increases Nuvation Bio (NYSE:NUVB) Price Target to $7.00

August 10, 2025 | marketbeat.com

Wedbush Reaffirms Their Buy Rating on Nuvation Bio (NUVB)

August 10, 2025 | theglobeandmail.com

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

August 10, 2025 | theglobeandmail.com

Wall Street Zen Downgrades Nuvation Bio (NYSE:NUVB) to Sell

August 10, 2025 | marketbeat.com

H.C. Wainwright Sticks to Their Buy Rating for Nuvation Bio (NUVB)

August 9, 2025 | theglobeandmail.com

NUVB Sales Jump 1,043% on Drug Launch

August 7, 2025 | aol.comA

Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates

August 7, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB, CRNX, ALVO, and HCM Company Descriptions

Alvotech NASDAQ:ALVO

$7.95 0.00 (0.00%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$7.94 0.00 (-0.06%)

As of 04:05 AM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Crinetics Pharmaceuticals NASDAQ:CRNX

$34.65 +1.35 (+4.05%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$35.41 +0.76 (+2.20%)

As of 04:40 AM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

HUTCHMED NASDAQ:HCM

$15.27 -0.05 (-0.33%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$15.33 +0.06 (+0.39%)

As of 04:02 AM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Nuvation Bio NYSE:NUVB

$3.16 +0.21 (+6.98%)

Closing price 09/3/2025 03:59 PM Eastern

Extended Trading

$3.26 +0.11 (+3.45%)

As of 05:14 AM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time